Streetbeat News

AZTR

Azitra, Inc.

Industry

Biotechnology

Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Azitra, Inc. has announced a registered direct offering of common stock, raising $930,000 by selling 3,339,300 shares at $0.2785 each.

Portfolio Pulse from

February 04, 2025 | 7:30 pm

Azitra, Inc., a clinical stage biopharmaceutical company, will present at the BIO CEO & Investor Conference on February 10-11, 2025, in New York City.

Portfolio Pulse from

February 03, 2025 | 2:15 pm

Azitra, Inc., a clinical stage biopharmaceutical company, will present at The Microcap Conference 2025 in Atlantic City, NJ. The company focuses on developing innovative therapies for precision dermatology.

Portfolio Pulse from

January 27, 2025 | 9:15 pm

Azitra, Inc. has announced the pricing of its public offering of 4,857,780 shares of common stock at $0.30 per share, raising $1.5 million. This move is part of their strategy to fund the development of therapies for precision dermatology.

Portfolio Pulse from

January 15, 2025 | 1:45 pm

Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company, has announced a public offering of its common stock. This move is aimed at raising capital for the company's operations and development of therapies in precision dermatology.

Portfolio Pulse from

January 14, 2025 | 9:15 pm

Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company, announced its Q3 2024 financial results and provided business updates. The company focuses on developing therapies for precision dermatology.

Portfolio Pulse from

November 12, 2024 | 10:15 pm

In Thursday's pre-market session, several healthcare stocks experienced significant movements. Notable gainers included Tevogen Bio Holdings, CNS Pharma, and DBV Technologies, while Conduit Pharmaceuticals, Genprex, and Ensysce Biosciences were among the losers.

Portfolio Pulse from Benzinga Insights

October 24, 2024 | 12:07 pm

In Thursday's pre-market session, several health care stocks experienced significant price movements. Notable gainers included Tevogen Bio Holdings, CNS Pharma, and DBV Technologies, while Conduit Pharmaceuticals, Genprex, and Ensysce Biosciences were among the losers.

Portfolio Pulse from Benzinga Insights

October 24, 2024 | 12:07 pm

Phoenix Motor Inc. (NASDAQ:PEV) shares surged 150.2% in pre-market trading after reporting a significant year-over-year increase in first-quarter financial results, with adjusted earnings of 44 cents per share and a 427.79% increase in sales. Other stocks also showed notable pre-market movements, including Vicinity Motor Corp, Biodesix, and Spirit Airlines, which is reportedly discussing potential bankruptcy.

Portfolio Pulse from Avi Kapoor

October 04, 2024 | 9:49 am

Azitra, Inc. (NYSE:AZTR) will present new findings on ATR-04, a treatment for EGFR inhibitor-induced skin toxicity, at the EADV Congress 2024. ATR-04 is a live biotherapeutic product in Phase 1/2 trials and has received Fast Track designation from the FDA.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 12:03 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.